Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02973100 · ClinicalTrials.gov registry record · Phase 2

A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

A Phase 2 study of Type 2 Diabetes, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
318
Enrollment target
20
Study locations

NCT02973100 is a Phase 2 study of Type 2 Diabetes that has completed, run by Eli Lilly and Company. The registered enrollment target is 318 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02973100, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
318 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Placebo
  • DRUG Dulaglutide

Study Locations (20)

California

  • Parexel Early Phase Unit at Glendale - Glendale
  • Marin Endocrine Associates - Greenbrae
  • National Research Institute - Huntington Park
  • National Research Institute - Los Angeles
  • Catalina Research Institute, LLC - Montclair
  • Artemis Institute for Clinical Research - San Diego
  • Encompass Clinical Research - Spring Valley Lake
  • University Clinical Investigators, Inc. - Tustin
  • Infosphere - Van Nuys
  • Diablo Clinical Research - Walnut Creek

Florida

  • Axes Medical Research, LLC - Cooper City
  • Clinical Research of South Florida - Coral Gables
  • East Coast Institute For Research - Jacksonville
  • New Horizon Research Center - Miami
  • Suncoast Research Group, LLC - Miami Lakes
  • Palm Harbor Medical Associates - Palm Harbor

Connecticut

  • Chase Medical Research, LLC - Waterbury

Georgia

  • In-Quest Medical Research, LLC - Norcross - Norcross

Hawaii

  • East West Medical Institute - Honolulu

Idaho

  • Elite Cilnical Trials LLLP - Blackfoot

Trial Details

FieldValue
Enrollment Target 318 participants
Start Date 2016-12
Est. Completion 2017-08-14
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02973100

The ClinicalTrials.gov registry entry for NCT02973100 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 318 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (71% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02973100 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Connecticut.

Frequently Asked Questions

What is clinical trial NCT02973100 about?

NCT02973100 is a clinical study titled "A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy". The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.

What is the current status of trial NCT02973100?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 318 participants. The study started on 2016-12. Estimated completion is 2017-08-14.

What conditions does trial NCT02973100 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT02973100?

The interventions under investigation include: Placebo (DRUG), Dulaglutide (DRUG).

Who is sponsoring clinical trial NCT02973100?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02973100 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.